The combination of positron emission tomography (PET) with either magnetic resonance imaging (MR) or computed tomography (CT) allows simultaneously acquiring information on biochemical receptors or metabolic pathways with PET at the same time as anatomical and blood flow with CT or MR.
PET radiopharmaceutical agents can visualize specific molecules inside the tissue molecular tissue to assist with diagnosis, interrogation of molecular pathways, targeted therapy, and monitoring response to therapy. The combination of PET with MRI allows simultaneous, precise co-registration of both anatomical and physiological information from any part of the body.
For imaging of traumatic brain injury (TBI), PET/MRI yields high resolution anatomical information about associated structural changes, in the brain, while PET allows the detection of early neuroinflammation and accumulation of tau proteins in neurodegeneration.
PET radiopharmaceuticals are provided through a partnership with PharmaLogic that operates a medical cyclotron and radiopharmacy just adjacent to the CURIC in the Bioscience 3 building.
The center also has active collaborations with the pharmaceutical industry to participate in clinical trials with new drug therapies or PET radiopharmaceuticals/ theranostics.